DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

It will provide care for a group of disorders that may progress to pulmonary fibrosis. Asian Hospital and Medical Centre ...

The following is a summary of “An exploratory analysis of differences in serum protein expression by sex in patients with ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

Sex-related differences in pulmonary complications were found among men vs women with SSc, specifically in the prevalence of ILD and SAD.

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) clearance from the U.S. Food and Drug Administration ...

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors ...

Mayo Clinic researchers find that stem cells with the highest Myc expression become dominant in driving lung remodeling .

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C ...